Boston-based Rhythm Pharmaceuticals has filed to be next in line for an initial public offering in the biotechnology sector.
In 2012, Scott Kirsner traced the winding origins of Chelsea company Civitas Therapeutics—a firm that seemingly breathed its last in 2008 after more than a decade of working on a way to deliver a broader range of drugs through an inhaler.
A little dishonesty can, maybe, in the right hands, used judiciously, be a tool that brings creativity to your business, suggests a study by Professor Francesca Gino of Harvard Business School and Scott S. Wiltermuth of the University of Southern California's Marshall School of Business. Read More
Changes could be coming at last to a largely squandered parcel in Cambridge’s Kendall Square, with implications for the life sciences and tech industries.